- Aug 14, 2013
- 2,455
- Tinnitus Since
- Resolved since 2016
- Cause of Tinnitus
- Unknown (medication, head injury)
Minor update on OTO-311...
I will try to get hold of some kind of information as to why the next step will be a phase I trial (and not a phase II trial) given that an initial trial had been conducted by another company already (i.e. "NeuroSystec"). I will also try to find out if the phase I trial is for healthy volunteers only.IND filing and start of Phase 1 clinical trial for OTO-311 expected in 2015:Otonomy plans to file an Investigational New Drug (IND) application with the FDA for OTO-311 and to initiate a Phase 1 clinical trial in 2015. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate, or NMDA, receptor antagonist gacyclidine in development for the treatment of tinnitus. In November 2014, Otonomy announced the completion of an exclusive license agreement with Ipsen that enables Otonomy to use clinical and non-clinical gacyclidine data generated by Ipsen to support worldwide development and regulatory filings for OTO-311.
Source: http://www.nasdaq.com/press-release...te-and-product-pipeline-update-20150108-01027